Skip to search formSkip to main contentSkip to account menu

Recentin

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
PURPOSE Cediranib is a highly potent inhibitor of vascular endothelial growth factor (VEGF) signaling with activity against all… 
2010
2010
2010
2010
Highly Cited
2009
Highly Cited
2009
PurposeCediranib (recentin, AZD2171) is an oral small-molecule multiple receptor tyrosine kinases inhibitor. Here we investigate… 
2009
2009
PurposeTo evaluate safety and tolerability of cediranib, a highly potent and selective vascular endothelial growth factor… 
Highly Cited
2009
Highly Cited
2009
Brain metastasis has become an increasing cause of morbidity and mortality in cancer patients as the treatment of systemic… 
Review
2009
Review
2009
Angiogenesis, the process whereby tumors develop new blood vessels to facilitate growth and metastasis, is a pivotal event in… 
Highly Cited
2008
Highly Cited
2008
Purpose: Inhibition of vascular endothelial growth factor-A (VEGF) signaling is a key therapeutic approach in oncology given the… 
Highly Cited
2008
Highly Cited
2008
Solid tumors express a range of factors required to sustain their growth and promote their dissemination. Among these are… 
2008
2008
A number of pre-clinical studies have suggested that blocking vascular endothelial growth factor (VEGF) signalling can be…